Salva Health develops a portable screening device that utilizes artificial intelligence to detect breast abnormalities, providing women in remote areas with access to early cancer detection. This technology addresses the lack of affordable and safe screening options, aiming to reduce breast cancer mortality rates globally.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Access to breast cancer screening is limited for women in remote areas due to the high costs, infrastructure requirements, and specialized personnel needed for traditional methods like mammography. This lack of access leads to late-stage diagnoses and increased mortality rates.
Solution
Salva Health has developed "Soy Julieta," a portable, AI-powered device for early breast cancer risk detection, designed to overcome barriers to access. The device uses electrical conductivity to analyze breast tissue and identify potential abnormalities without radiation, making it safe and accessible in remote areas. The AI algorithms automate the test and interpret results in real-time, classifying tissue as healthy or potentially cancerous, and prioritizing women at risk for further evaluation. This technology aims to provide a cost-effective, portable, and easy-to-use screening solution, enabling frequent and early detection of breast cancer risks, particularly in underserved communities.
Target Audience
The primary target audience includes women in remote and underserved areas with limited access to traditional screening methods, as well as healthcare providers and organizations seeking to expand access to affordable and effective breast cancer screening.
Features
- Portable and wireless design for use in remote locations without specialized infrastructure
- AI-powered analysis for automated test execution and real-time results interpretation
- Electrical conductivity-based tissue analysis, eliminating radiation exposure
- Integration with a cloud-based platform for data storage and analysis
- High accuracy in identifying potential abnormalities, validated through clinical studies with over 2,000 patients
- Easy-to-use interface, enabling operation by individuals with basic training
- Rechargeable battery for use in areas with limited access to electricity